A 7-Day Losing Streak Has Mettler-Toledo International Stock Down 8.9%
A steady decline in the life sciences company’s stock prompts a closer look at its underlying business metrics.
A seven-day slide in Mettler-Toledo International (MTD) stock has erased about $2.5 billion from the company’s market value. The stock has now moved lower for 7 consecutive trading days, shedding a cumulative 8.9% over that period and leaving its market capitalization at about $26 billion.
For anyone who entered the stock over the past month, the persistent decline has quickly eroded near-term gains, even as longer-term three-month holders remain up 13.0%.
MTD Versus The S&P 500, Streak And Beyond
Here is how MTD stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | MTD | S&P 500 |
|---|---|---|
| 1D | -0.8% | -0.6% |
| 7D (Current Streak) | -8.9% | -1.2% |
| 1M (21D) | -10.9% | -1.8% |
| 3M (63D) | 13.0% | 4.5% |
| YTD 2026 | -8.1% | 10.9% |
| 2025 | 13.9% | 16.4% |
| 2024 | 0.9% | 23.3% |
| 2023 | -16.1% | 24.2% |
How Do The Company’s Fundamentals Look?
The data presents a mixed picture, though the sources do not point to a specific cause behind the recent streak. The stock’s recent move appears to be its own story, as its 8.9% loss came over a period when the S&P 500 returned -1.2%. While a streak of this length draws attention, it is not unique; 7 other S&P 500 stocks are currently on losing streaks of 7 days or more.
Fundamentally, the company’s operating margin of 28.4% is well above the S&P 500 median of 18.6%, and its free cash flow yield stands at 3.4%. However, its revenue growth over the last twelve months was 6.9%, trailing the index median of 8.3%, and its 3-year average annual revenue growth is 1.6%. The stock also trades at a price-to-earnings multiple of 28.5, above the S&P 500 median of 22.6 and the Health Care sector median of 25.0.
So What Does A Seven-Day Streak Actually Tell An Investor?
A streak is information, not an instruction. It tells you where market momentum and attention have been focused, but it does not predict where they will go next. A string of losses or gains is not, by itself, a reason to act.
The disciplined move is to treat the streak as a prompt to check your thesis. It is an opportunity to weigh the facts of the business against the price the market is offering. The numbers here are a starting point for that work.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
And for anyone who would rather back the theme than one company’s story, our ETF Scorecard shows how the healthcare funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Falling Prices Test Conviction. Rules Do Not Flinch
A losing streak forces a choice on every holder: sell into weakness, average down, or freeze. All three are emotional answers to what should be an analytical question, and emotions priced at market open are expensive.
The Trefis High Quality (HQ) Portfolio takes the emotion out: about 30 quality businesses screened for the fundamentals that survive bad stretches, held and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the rules do the heavy lifting for you.